MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings EBITDA 2011-2026 | ONVO
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.4 M | -14.8 M | -17.4 M | -16.8 M | -20.6 M | -26.3 M | -34 M | -37.4 M | -37.8 M | -29.8 M | -20.3 M | -3.95 M | -9.12 M | -118 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -118 K | -37.8 M | -20.1 M |
Quarterly EBITDA Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -2.85 M | - | - | - | -3.32 M | - | - | - | -4.13 M | - | -3.36 M | -3.12 M | -3.19 M | - | -3.5 M | -9.47 M | -6.01 M | - | -2.49 M | -2.47 M | -8.94 M | -2.78 M | -5.23 M | -4.1 M | -6.45 M | -6.32 M | -6.53 M | -5.7 M | -5.44 M | - | -7.91 M | -9.58 M | -9.87 M | - | -9.63 M | -27.1 M | -17.8 M | - | -10.5 M | -29.7 M | -19.4 M | - | -6.96 M | -22 M | -15.2 M | - | -4.63 M | -13.7 M | -9.15 M | -3.94 M | -2.92 M | -7.81 M | -4.97 M | -1.31 M | - | -573 K | -441 K | -476 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -441 K | -29.7 M | -7.69 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.67 B | $ 110.28 | -2.82 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-81.4 M | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
70.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
94.9 M | $ 13.21 | -2.44 % | $ 3.75 B | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.8 M | - | - | $ 9.42 M |  Israel |
 |
Heska Corporation
HSKA
|
-6.33 M | - | - | $ 1.31 B | USA |
|
Biodesix
BDSX
|
-28.7 M | $ 14.31 | -2.02 % | $ 1.86 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M |  Britain |
 |
Burning Rock Biotech Limited
BNR
|
-749 M | $ 16.41 | -11.3 % | $ 177 M |  China |
 |
BioNano Genomics
BNGO
|
-23.8 M | $ 1.15 | -0.43 % | $ 6.26 M | USA |
 |
Bioventus
BVS
|
101 M | $ 9.03 | -2.48 % | $ 602 M | USA |
 |
Co-Diagnostics
CODX
|
-41.5 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
-32.5 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
1.16 B | $ 62.84 | -4.93 % | $ 24.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-12.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
Fulgent Genetics
FLGT
|
-49 M | $ 15.54 | -5.13 % | $ 470 M | USA |
 |
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-398 M | $ 84.0 | -4.65 % | $ 10.5 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
24.7 M | $ 24.0 | -2.83 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
428 M | $ 158.89 | -3.78 % | $ 7.88 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 195.64 | -1.27 % | $ 21.7 B | USA |
 |
OpGen
OPGN
|
499 K | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
-36.3 M | $ 8.45 | - | $ 33.7 M | Israel |
 |
ICON Public Limited Company
ICLR
|
1.59 B | $ 102.3 | -0.76 % | $ 8.44 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.51 B | $ 561.97 | -1.98 % | $ 45.2 B | USA |
 |
Biocept
BIOC
|
-30.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Illumina
ILMN
|
-479 M | $ 117.62 | -5.45 % | $ 18.7 B | USA |
 |
PerkinElmer
PKI
|
762 M | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
47.2 M | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
8.41 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Medpace Holdings
MEDP
|
562 M | $ 452.91 | -2.94 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 233.1 | -2.91 % | $ 25.4 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
-334 M | $ 4.38 | -5.19 % | $ 406 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.26 | -7.19 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
-79.8 M | $ 7.35 | -5.28 % | $ 942 M | USA |
 |
IQVIA Holdings
IQV
|
3.33 B | $ 164.54 | -2.87 % | $ 28.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.5 M | - | -34.28 % | $ 263 K | Israel |
 |
National Research Corporation
NRC
|
30.2 M | $ 17.2 | -0.95 % | $ 385 M | USA |
 |
QIAGEN N.V.
QGEN
|
301 M | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
-524 M | $ 184.45 | -5.96 % | $ 18.2 B | USA |
 |
OPKO Health
OPK
|
-53.9 M | $ 1.15 | -1.79 % | $ 798 M | USA |